While these findings underscore the promise of incretin therapies for OSA management, the review emphasizes the need for long-term follow-up to assess durability of benefit and monitor safety
CT-measured visceral fat fell about 15% over 26 weeks in Phase III trials, with the change reversing within about 26 weeks after stopping
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
This symptom is common in people with a B12 deficiency
Results Nineteen studies met inclusion criteria: four RCTs ( n = 1,884 participants), five retrospective cohort studies ( n = 1,122,653 participants), three pharmacovigilance analyses ( n = 498,892 spontaneous adverse-event reports), and seven case reports or case series ( n = 13 patients)
C.van de Poll-FranseL